Clinical  ||| S:0 E:9 ||| JJ
relevance  ||| S:9 E:19 ||| NN
of  ||| S:19 E:22 ||| IN
monoclonal  ||| S:22 E:33 ||| JJ
antibodies  ||| S:33 E:44 ||| NNS
in  ||| S:44 E:47 ||| IN
non  ||| S:47 E:51 ||| JJ
small  ||| S:51 E:57 ||| JJ
cell  ||| S:57 E:62 ||| NN
lung  ||| S:62 E:67 ||| NN
cancer  ||| S:67 E:74 ||| NN
Targeted  ||| S:74 E:83 ||| NNP
therapies  ||| S:83 E:93 ||| NNS
with  ||| S:93 E:98 ||| IN
monoclonal  ||| S:98 E:109 ||| JJ
antibodies  ||| S:109 E:120 ||| NNS
have  ||| S:120 E:125 ||| VBP
been  ||| S:125 E:130 ||| VBN
shown  ||| S:130 E:136 ||| VBN
to  ||| S:136 E:139 ||| TO
improve  ||| S:139 E:147 ||| VB
the  ||| S:147 E:151 ||| DT
outcome  ||| S:151 E:159 ||| NN
of  ||| S:159 E:162 ||| IN
non-small  ||| S:162 E:172 ||| JJ
cell  ||| S:172 E:177 ||| NN
lung  ||| S:177 E:182 ||| NN
cancer  ||| S:182 E:189 ||| NN
( ||| S:189 E:190 ||| -LRB-
NSCLC ||| S:190 E:195 ||| NNP
) ||| S:195 E:196 ||| -RRB-
.  ||| S:196 E:198 ||| .
Current  ||| S:198 E:206 ||| JJ
strategies  ||| S:206 E:217 ||| NNS
focus  ||| S:217 E:223 ||| VBP
on  ||| S:223 E:226 ||| IN
the  ||| S:226 E:230 ||| DT
blockade  ||| S:230 E:239 ||| NN
of  ||| S:239 E:242 ||| IN
growth  ||| S:242 E:249 ||| NN
factor  ||| S:249 E:256 ||| NN
receptors  ||| S:256 E:266 ||| NNS
and  ||| S:266 E:270 ||| CC
the  ||| S:270 E:274 ||| DT
inhibition  ||| S:274 E:285 ||| NN
of  ||| S:285 E:288 ||| IN
angiogenesis ||| S:288 E:300 ||| NN
.  ||| S:300 E:302 ||| .
Epidermal  ||| S:302 E:312 ||| JJ
growth  ||| S:312 E:319 ||| NN
factor  ||| S:319 E:326 ||| NN
receptor  ||| S:326 E:335 ||| NN
( ||| S:335 E:336 ||| -LRB-
EGFR ||| S:336 E:340 ||| NNP
) ||| S:340 E:341 ||| -RRB-
-directed  ||| S:341 E:351 ||| JJ
monoclonal  ||| S:351 E:362 ||| JJ
antibodies  ||| S:362 E:373 ||| NNS
in  ||| S:373 E:376 ||| IN
combination  ||| S:376 E:388 ||| NN
with  ||| S:388 E:393 ||| IN
platinum-based  ||| S:393 E:408 ||| JJ
first-line  ||| S:408 E:419 ||| JJ
chemotherapy  ||| S:419 E:432 ||| NNS
have  ||| S:432 E:437 ||| VBP
shown  ||| S:437 E:443 ||| VBN
promising  ||| S:443 E:453 ||| JJ
efficacy  ||| S:453 E:462 ||| NN
in  ||| S:462 E:465 ||| IN
phase  ||| S:465 E:471 ||| NN
II  ||| S:471 E:474 ||| NNP
trials ||| S:474 E:480 ||| NNS
.  ||| S:480 E:482 ||| .
In  ||| S:482 E:485 ||| IN
a  ||| S:485 E:487 ||| DT
phase  ||| S:487 E:493 ||| NN
III  ||| S:493 E:497 ||| NNP
trial ||| S:497 E:502 ||| NN
,  ||| S:502 E:504 ||| ,
cetuximab  ||| S:504 E:514 ||| VBD
combined  ||| S:514 E:523 ||| VBN
with  ||| S:523 E:528 ||| IN
cisplatin ||| S:528 E:537 ||| CD
/  ||| S:537 E:539 ||| CD
vinorelbine  ||| S:539 E:551 ||| NNS
resulted  ||| S:551 E:560 ||| VBD
in  ||| S:560 E:563 ||| IN
superior  ||| S:563 E:572 ||| JJ
survival  ||| S:572 E:581 ||| NN
compared  ||| S:581 E:590 ||| VBN
to  ||| S:590 E:593 ||| TO
chemotherapy  ||| S:593 E:606 ||| VB
alone  ||| S:606 E:612 ||| RB
in  ||| S:612 E:615 ||| IN
patients  ||| S:615 E:624 ||| NNS
with  ||| S:624 E:629 ||| IN
advanced  ||| S:629 E:638 ||| JJ
EGFR-positive  ||| S:638 E:652 ||| JJ
NSCLC ||| S:652 E:657 ||| NNP
.  ||| S:657 E:659 ||| .
Inhibition  ||| S:659 E:670 ||| NNP
of  ||| S:670 E:673 ||| IN
angiogenesis  ||| S:673 E:686 ||| NN
has  ||| S:686 E:690 ||| VBZ
also  ||| S:690 E:695 ||| RB
been  ||| S:695 E:700 ||| VBN
successfully  ||| S:700 E:713 ||| RB
applied  ||| S:713 E:721 ||| VBN
as  ||| S:721 E:724 ||| IN
a  ||| S:724 E:726 ||| DT
new  ||| S:726 E:730 ||| JJ
treatment  ||| S:730 E:740 ||| NN
strategy ||| S:740 E:748 ||| NN
.  ||| S:748 E:750 ||| .
Bevacizumab  ||| S:750 E:762 ||| NNP
added  ||| S:762 E:768 ||| VBD
to  ||| S:768 E:771 ||| TO
palliative  ||| S:771 E:782 ||| VB
chemotherapy  ||| S:782 E:795 ||| NN
has  ||| S:795 E:799 ||| VBZ
improved  ||| S:799 E:808 ||| VBN
progression-free  ||| S:808 E:825 ||| JJ
survival  ||| S:825 E:834 ||| NN
in  ||| S:834 E:837 ||| IN
two  ||| S:837 E:841 ||| CD
phase  ||| S:841 E:847 ||| NN
III  ||| S:847 E:851 ||| NNP
trials  ||| S:851 E:858 ||| NNS
and  ||| S:858 E:862 ||| CC
overall  ||| S:862 E:870 ||| JJ
survival  ||| S:870 E:879 ||| NN
in  ||| S:879 E:882 ||| IN
one  ||| S:882 E:886 ||| CD
of  ||| S:886 E:889 ||| IN
these  ||| S:889 E:895 ||| DT
trials  ||| S:895 E:902 ||| NNS
in  ||| S:902 E:905 ||| IN
selected  ||| S:905 E:914 ||| JJ
patients  ||| S:914 E:923 ||| NNS
with  ||| S:923 E:928 ||| IN
advanced  ||| S:928 E:937 ||| JJ
non-squamous  ||| S:937 E:950 ||| JJ
cell  ||| S:950 E:955 ||| NN
lung  ||| S:955 E:960 ||| NN
cancer ||| S:960 E:966 ||| NN
.  ||| S:966 E:968 ||| .
Bevacizumab  ||| S:968 E:980 ||| NNP
is  ||| S:980 E:983 ||| VBZ
now  ||| S:983 E:987 ||| RB
approved  ||| S:987 E:996 ||| VBN
for  ||| S:996 E:1000 ||| IN
selected  ||| S:1000 E:1009 ||| JJ
patients  ||| S:1009 E:1018 ||| NNS
with  ||| S:1018 E:1023 ||| IN
advanced  ||| S:1023 E:1032 ||| JJ
NSCLC  ||| S:1032 E:1038 ||| NN
in  ||| S:1038 E:1041 ||| IN
combination  ||| S:1041 E:1053 ||| NN
with  ||| S:1053 E:1058 ||| IN
platinum-based  ||| S:1058 E:1073 ||| JJ
chemotherapy ||| S:1073 E:1085 ||| NN
.  ||| S:1085 E:1087 ||| .
Figitumumab  ||| S:1087 E:1099 ||| NNP
is  ||| S:1099 E:1102 ||| VBZ
a  ||| S:1102 E:1104 ||| DT
monoclonal  ||| S:1104 E:1115 ||| JJ
antibody  ||| S:1115 E:1124 ||| NN
against  ||| S:1124 E:1132 ||| IN
the  ||| S:1132 E:1136 ||| DT
insulin-like  ||| S:1136 E:1149 ||| JJ
growth  ||| S:1149 E:1156 ||| NN
factor-1  ||| S:1156 E:1165 ||| CD
receptor  ||| S:1165 E:1174 ||| NN
( ||| S:1174 E:1175 ||| -LRB-
IGF-1R ||| S:1175 E:1181 ||| NNP
)  ||| S:1181 E:1183 ||| -RRB-
which  ||| S:1183 E:1189 ||| WDT
demonstrated  ||| S:1189 E:1202 ||| VBD
activity  ||| S:1202 E:1211 ||| NN
in  ||| S:1211 E:1214 ||| IN
preclinical  ||| S:1214 E:1226 ||| JJ
models  ||| S:1226 E:1233 ||| NNS
of  ||| S:1233 E:1236 ||| IN
NSCLC  ||| S:1236 E:1242 ||| NNP
and  ||| S:1242 E:1246 ||| CC
in  ||| S:1246 E:1249 ||| IN
a  ||| S:1249 E:1251 ||| DT
phase  ||| S:1251 E:1257 ||| NN
II  ||| S:1257 E:1260 ||| NNP
trial ||| S:1260 E:1265 ||| NN
.  ||| S:1265 E:1267 ||| .
Because  ||| S:1267 E:1275 ||| IN
of  ||| S:1275 E:1278 ||| IN
these  ||| S:1278 E:1284 ||| DT
promising  ||| S:1284 E:1294 ||| JJ
results ||| S:1294 E:1301 ||| NNS
,  ||| S:1301 E:1303 ||| ,
three  ||| S:1303 E:1309 ||| CD
randomized ||| S:1309 E:1319 ||| NN
,  ||| S:1319 E:1321 ||| ,
open-label ||| S:1321 E:1331 ||| NNP
,  ||| S:1331 E:1333 ||| ,
international  ||| S:1333 E:1347 ||| JJ
phase  ||| S:1347 E:1353 ||| NN
III  ||| S:1353 E:1357 ||| NNP
trials  ||| S:1357 E:1364 ||| NNS
of  ||| S:1364 E:1367 ||| IN
figitumumab  ||| S:1367 E:1379 ||| NN
in  ||| S:1379 E:1382 ||| IN
patients  ||| S:1382 E:1391 ||| NNS
with  ||| S:1391 E:1396 ||| IN
locally  ||| S:1396 E:1404 ||| RB
advanced  ||| S:1404 E:1413 ||| VBN
or  ||| S:1413 E:1416 ||| CC
metastatic  ||| S:1416 E:1427 ||| JJ
NSCLC  ||| S:1427 E:1433 ||| NNS
are  ||| S:1433 E:1437 ||| VBP
in  ||| S:1437 E:1440 ||| IN
progress ||| S:1440 E:1448 ||| NN
.  ||| S:1448 E:1450 ||| .
